ScholarLens Back to search
2014•American Heart JournalRequires access

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Christopher Bull Granger, Renato D. Lópes, Michael G. Hanna, Jack Ansell, Elaine M. Hylek, John Hunter Alexander, Laine Elliott Thomas, Junyuan Wang, Maria Cecilia Bahit, Freek W.A. Verheugt, Jack Lawrence, Denis Xavier, Lars C. Wallentin

Open publisher page 71 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 71 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Apixaban, Warfarin, Medicine, Discontinuation, Atrial fibrillation, Stroke (engine), Vitamin K antagonist, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial — Research Paper | ScholarLens